UBS lowered the firm’s price target on Iqvia (IQV) to $185 from $255 and keeps a Buy rating on the shares. The Technology & Analytics Solutions recovery is on track, but the firm sees incremental weakness in Research & Development Solutions, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $161 from $195 at Baird
- IQVIA Holdings: Strong Financial Performance and Promising Outlook Amidst Market Challenges
- Iqvia price target lowered to $165 from $170 at Barclays
- IQVIA Holdings Reports Strong Q1 2025 Results
- Resilience and Growth Prospects Drive Buy Rating for IQVIA Holdings Amid Industry Challenges